Media Inquiries

If you are interested in interviewing a CCR scientist, OR you are a scientist who has been contacted by a member of the media, please contact the NCI Press Office at ncipressofficers@mail.nih.gov or by phone at 240.760.6600.

News and Events

CD45R-stained IHC image depicting B cells within a tertiary lymphoid structure in a triple-treated cholangiocarcinoma tumor

Study uncovers mechanism behind effectiveness of three-drug combination in patients with a rare bile duct cancer

Combining anti-VEGF therapy with immune checkpoint inhibitors stimulated the production of B cells to fight cholangiocarcinoma, a rare bile duct cancer.

Scans of a woman with breast cancer before and after TIL therapy.

NCI study advances personalized immunotherapy for metastatic breast cancer

An experimental form of immunotherapy that uses an individual’s own tumor-fighting immune cells could potentially be used to treat people with metastatic breast cancer, according to results from an ongoing clinical trial led by Steven A. Rosenberg, M.D., Ph.D., Chief of the Surgery Branch.

All about the drive: A rare kidney cancer meets its match at NIH

On New Year’s Eve, 2020, Katie Coleman was diagnosed with a very rare form of advanced kidney cancer. She enrolled in a clinical trial led by a collaborative CCR team that gave her the opportunity to have surgery in hopes of removing her tumors.

Cartoon illustration showing how a variety of cell types surround and interact with cancer cells

Researchers develop new method to estimate cell-type-specific information from bulk tumor data

CCR researchers have established a way to extract cell-type-specific expression information from bulk gene expression data of a tumor sample. Their computational approach, which outperforms comparable state-of-the-art methods, evaluates thousands of tumor samples with minimal cost.

Breast cancer stem cells become aggressive upon contact with macrophages

New findings suggest that breast cancer cells gain stem-like characteristics of invasiveness, aggressiveness and drug resistance upon contact with macrophages, specialized white blood cells in the immune system.

A high-fiber diet may improve the response of melanoma patients to immunotherapy

A new study co-led by Giorgio Trinchieri, M.D., chief of the Laboratory of Integrative Cancer Immunology, found that a diet rich in fiber may help some people being treated for melanoma respond to immunotherapy treatment by influencing the gut microbiome. The new findings come from an analysis of people with melanoma and mouse models of the disease.

Cell surface molecule could predict how patients respond to immunotherapy

A new study finds that some immunotherapy drugs are less likely to control cancer in patients who carry HLA-A*03, a cell surface molecule that is involved in immune system responses. This work, which was featured in NCI's Cancer Currents, reveals that HLA-A*03 is a potential biomarker for patient prognosis following certain immunotherapy treatments.

Clinical trial researches drug combination with immunotherapy for mesothelioma

Mesothelioma is a rare, fast-growing cancer that forms in membranes that surround and protect the heart, lungs and abdomen. The cells of malignant mesothelioma express large amounts of mesothelin, a cancerous protein. Investigators are researching a mesothelin-targeting drug in combination with immunotherapy.

GPC3 expression in hepatocellular carcinoma

Clinical trial targets cell surface protein GPC3 to treat advanced hepatocellular carcinoma

Tim F. Greten, M.D., Deputy Chief of the Thoracic and GI Malignancies Branch, is leading a study of advanced hepatocellular carcinoma, a common type of liver cancer with a poor prognosis. The research uses CAR T-cell therapy to target GPC3-positive tumor cells while avoiding healthy tissue.

artist depiction of a tumor microenvironment

CCR researchers use immunogenetic profiling to identify targets for numerous pediatric cancers

Researchers analyzed over 700 pediatric tumor samples and cell lines, creating one of the largest profile datasets of gene expression and immune response in solid pediatric tumors to date. Their work reveals that a germline developmental protein called PRAME is a potential cancer target.

Anish Thomas explains the challenges and goals of his small cell lung cancer research

Anish Thomas, M.B.B.S., M.D., Lasker Clinical Research Scholar in the Developmental Therapeutics Branch, studies small cell lung cancer (SCLC). For Lung Cancer Awareness Month, Thomas describes his current research interests and his goals to help improve the lives of patients with SCLC – the most lethal type of lung cancer.

Breadcrumb

News and Events